Tumour blood flow for prediction of human prostate cancer aggressiveness - A study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Tumour blood flow for prediction of human prostate cancer aggressiveness - A study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density. / Jochumsen, Mads Ryø; Sørensen, Jens; Pedersen, Bodil Ginnerup et al.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, No. 2, 02.2021, p. 532-542.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{e25fdaadda184c7c9d7f61c13eef08aa,
title = "Tumour blood flow for prediction of human prostate cancer aggressiveness - A study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density",
abstract = "Purpose: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 ( 82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to determine the ability of TBF for separating significant from insignificant PCa and to examine the relation to underlying Na +/K +-ATPase density, which is relevant as 82Rb is transported intracellularly via the Na +/K +-ATPase. Methods: One hundred and two patients were included for pelvic 82Rb PET scan prior to magnetic resonance imaging (MRI)-guided prostate biopsy. Findings constituted 100 PCa lesions (86 patients) and 25 benign lesions (16 patients). Tumours were defined on MRI and transferred to 82Rb PET for TBF measurement. Immunohistochemical Na +/K +-ATPase staining was subsequently performed on biopsies. Results: TBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = −0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na +/K +-ATPase density per PCa cell profile was 38% lower compared with that of the benign prostate cell profiles. Neither cell density nor Na +/K +-ATPase density determined tumour 82Rb uptake. Conclusion: TBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa. ",
keywords = "ISUP grade group, Na /K -ATPase, Prostate cancer, Rubidium-82, Tumour blood flow, DCE-MRI, NA,K-ATPASE, K+-ATPase, PARAMETERS, EXCRETION, GLEASON GRADE, Na+, CARCINOMA, EXPRESSION, GA-68-PSMA-11 PET/CT, Humans, Male, Prostatic Neoplasms/diagnostic imaging, Tomography, X-Ray Computed, Positron-Emission Tomography, Magnetic Resonance Imaging, Adenosine Triphosphatases, Rubidium Radioisotopes",
author = "Jochumsen, {Mads Ry{\o}} and Jens S{\o}rensen and Pedersen, {Bodil Ginnerup} and Nyengaard, {Jens Randel} and Krag, {S{\o}ren Rasmus Palmelund} and J{\o}rgen Fr{\o}ki{\ae}r and Michael Borre and Kirsten Bouchelouche and Tolbod, {Lars Poulsen}",
year = "2021",
month = feb,
doi = "10.1007/s00259-020-04998-2",
language = "English",
volume = "48",
pages = "532--542",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Tumour blood flow for prediction of human prostate cancer aggressiveness - A study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density

AU - Jochumsen, Mads Ryø

AU - Sørensen, Jens

AU - Pedersen, Bodil Ginnerup

AU - Nyengaard, Jens Randel

AU - Krag, Søren Rasmus Palmelund

AU - Frøkiær, Jørgen

AU - Borre, Michael

AU - Bouchelouche, Kirsten

AU - Tolbod, Lars Poulsen

PY - 2021/2

Y1 - 2021/2

N2 - Purpose: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 ( 82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to determine the ability of TBF for separating significant from insignificant PCa and to examine the relation to underlying Na +/K +-ATPase density, which is relevant as 82Rb is transported intracellularly via the Na +/K +-ATPase. Methods: One hundred and two patients were included for pelvic 82Rb PET scan prior to magnetic resonance imaging (MRI)-guided prostate biopsy. Findings constituted 100 PCa lesions (86 patients) and 25 benign lesions (16 patients). Tumours were defined on MRI and transferred to 82Rb PET for TBF measurement. Immunohistochemical Na +/K +-ATPase staining was subsequently performed on biopsies. Results: TBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = −0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na +/K +-ATPase density per PCa cell profile was 38% lower compared with that of the benign prostate cell profiles. Neither cell density nor Na +/K +-ATPase density determined tumour 82Rb uptake. Conclusion: TBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa.

AB - Purpose: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 ( 82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to determine the ability of TBF for separating significant from insignificant PCa and to examine the relation to underlying Na +/K +-ATPase density, which is relevant as 82Rb is transported intracellularly via the Na +/K +-ATPase. Methods: One hundred and two patients were included for pelvic 82Rb PET scan prior to magnetic resonance imaging (MRI)-guided prostate biopsy. Findings constituted 100 PCa lesions (86 patients) and 25 benign lesions (16 patients). Tumours were defined on MRI and transferred to 82Rb PET for TBF measurement. Immunohistochemical Na +/K +-ATPase staining was subsequently performed on biopsies. Results: TBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = −0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na +/K +-ATPase density per PCa cell profile was 38% lower compared with that of the benign prostate cell profiles. Neither cell density nor Na +/K +-ATPase density determined tumour 82Rb uptake. Conclusion: TBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa.

KW - ISUP grade group

KW - Na /K -ATPase

KW - Prostate cancer

KW - Rubidium-82

KW - Tumour blood flow

KW - DCE-MRI

KW - NA,K-ATPASE

KW - K+-ATPase

KW - PARAMETERS

KW - EXCRETION

KW - GLEASON GRADE

KW - Na+

KW - CARCINOMA

KW - EXPRESSION

KW - GA-68-PSMA-11 PET/CT

KW - Humans

KW - Male

KW - Prostatic Neoplasms/diagnostic imaging

KW - Tomography, X-Ray Computed

KW - Positron-Emission Tomography

KW - Magnetic Resonance Imaging

KW - Adenosine Triphosphatases

KW - Rubidium Radioisotopes

UR - http://www.scopus.com/inward/record.url?scp=85089472560&partnerID=8YFLogxK

U2 - 10.1007/s00259-020-04998-2

DO - 10.1007/s00259-020-04998-2

M3 - Journal article

C2 - 32808078

VL - 48

SP - 532

EP - 542

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 2

ER -